Adrenal disease

Do multiple types of confirmatory tests improve performance in predicting subtypes of primary aldosteronism?

Clin Endocrinol (Oxf)Published Cross-sectional study

Authors' conclusion

Our data suggest that patients with positive case detection undergo one confirmatory test to determine the indication for AVS.

Study context

Population
Patients with primary aldosteronism (PA) who underwent saline infusion test (SIT) and captopril challenge test (CCT) and were subtyped by adrenal venous sampling (AVS) (unilateral, n = 99; bilateral, n = 516), referral centrestraining and test data sets
Participants
615 patients
Exposure
SIT + CCT combination vs SIT alone vs CCT alone for predicting PA subtype
Outcome
AUC and clinical usefulness (decision curve analysis) for subtype prediction in the test data set
Methodological detailsretrospective, referral centres, machine learning, training and test data sets
  • Retrospective
  • Referral centres
  • Machine learning
  • Training and test data sets

Main finding

As reported in the abstract

AUC for PA subtype prediction (test data set)
GroupAUC
SIT + CCT0.850
SIT0.813
CCT0.786

AUC

SIT + CCT0.850
SIT0.813
CCT0.786

Observational data: associations, not effects.

Further findings

AUC of baseline clinical characteristics alone and combined with confirmatory tests

Baseline clinical characteristics alone, AUC
0.872
Clinical characteristics + SIT, AUC
0.868
Clinical characteristics + CCT, AUC
0.854
Clinical characteristics + SIT + CCT, AUC
0.855
No significant improvement in AUC

Decision curve analysis

Additional clinical usefulness of the second confirmatory test was unremarkable

Original publication

Do multiple types of confirmatory tests improve performance in predicting subtypes of primary aldosteronism? Clin Endocrinol (Oxf). Published 1 December 2022. doi:10.1111/cen.14854

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.